Literature DB >> 26248511

Use of low dose rVSV-ZEBOV: safety issues in a Swiss cohort.

Julie E Ledgerwood1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26248511     DOI： 10.1016/S1473-3099(15)00222-4

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN： 1473-3099            Impact factor:   25.071


× No keyword cloud information.
  4 in total

1.  A Replicating Single-Cycle Adenovirus Vaccine Against Ebola Virus.

Authors:  Stephanie S Anguiano-Zarate; William E Matchett; Pramod N Nehete; Jagannadha K Sastry; Andrea Marzi; Michael A Barry
Journal:  J Infect Dis       Date:  2018-11-05       Impact factor: 5.226

2.  Clinical validation trial of a diagnostic for Ebola Zaire antigen detection: Design rationale and challenges to implementation.

Authors:  John Schieffelin; Lina M Moses; Jeffrey Shaffer; Augustine Goba; Donald S Grant
Journal:  Clin Trials       Date:  2016-01-14       Impact factor: 2.486

Review 3.  Advances in gene-based vaccine platforms to address the COVID-19 pandemic.

Authors:  Deborah Pushparajah; Salma Jimenez; Shirley Wong; Hibah Alattas; Nafiseh Nafissi; Roderick A Slavcev
Journal:  Adv Drug Deliv Rev       Date:  2021-01-07       Impact factor: 17.873

4.  Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial.

Authors:  Selidji T Agnandji; José F Fernandes; Emmanuel B Bache; Régis M Obiang Mba; Jessica S Brosnahan; Lumeka Kabwende; Paul Pitzinger; Pieter Staarink; Marguerite Massinga-Loembe; Verena Krähling; Nadine Biedenkopf; Sarah Katharina Fehling; Thomas Strecker; David J Clark; Henry M Staines; Jay W Hooper; Peter Silvera; Vasee Moorthy; Marie-Paule Kieny; Akim A Adegnika; Martin P Grobusch; Stephan Becker; Michael Ramharter; Benjamin Mordmüller; Bertrand Lell; Sanjeev Krishna; Peter G Kremsner
Journal:  PLoS Med       Date:  2017-10-06       Impact factor: 11.069
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.